Within the last few years the importance of the internal mammary artery (IMA) for coronary revascularization has increased rapidly. Although there is no doubt about the superior long-term patency of this artery in comparison to saphenous vein grafts, the discussion about early postoperative results ...
Over the past 5 years, early diagnosis of and new treatments for cardiac amyloidosis (CA) have emerged that hold promise for early intervention. These include non-invasive diagnostic tests and disease modifying therapies. Recently, CA has been one of the first types of cardiomyopathy to be ...
New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis. Amyloid 2012;19: 99-105.O. Leone, S. Longhi, C. C. Quarta et al., "New pathological insights into cardiac amyloidosis: implications for non- invasive diagnosis," Amyloid, vol. 19, no. 2, pp. 99-...
Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid. 2009;16:63-70.Maria Cristina Porciani, Alessio Lilli, Federico Perfetto, Francesco Cappelli, Carmelo Massimiliano Rao, Stefano Del Pace, Mauro Ciaccheri, Gabriele Castelli, Roberto Tarquini, Lara ...
Like polyneuropathy, cardiac amyloidosis is a prominent clinical feature of hereditary amyloidosis, namely of the autosomal dominant transthyretin (TTR) type. All 28 cases of TTR amyloidoses reported so far were heterozygotes for a single nucleotide change in the gene for TTR that resulted in amino...
Amvuttra (vutrisiran) is an RNAi therapeutic for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis and cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis. Alnylam Announces FDA Approval of Amvuttra (vutrisiran), the First RNAi Therapeutic to Reduce...
The design and application of dual-targeted and multi-targeted inhibitors place a greater emphasis on the interrelations of pathological factors, enhancing the convenience of medication for patients. Multi-target drugs can act on multiple interconnected targets in AD. Although their activity on a ...
It is the first and only FDA-approved steroid-free topical medication in its class. Dermavant Sciences- Vutrisiran (Amvuttra), a transthyretin-directed siRNA used to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis. It is a small interfering RNA that interferes with ...
(Coelho et al.2023). Eplontersen is similar to inotersen, which was approved by the FDA in 2018 to treat hereditary transthyretin amyloidosis (Benson et al.2018). Eplontersen has been approved for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and received orphan drug ...
The Aβ hypothesis is the mainstream hypothesis for the pathogenesis of AD and has influenced the direction of drug development over the past three decades. According to the hypothesis, the pathological progression of AD originates from asymptomatic cerebral amyloidosis many years before the onset of...